2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

4:30PM-6:00PM: Abstract Number: 2130

Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Low-Dose Aspirin: A Case-Crossover Study

Rheumatoid Arthritis - Clinical Aspects III - Cardiovascular Disease and RA

4:30PM-6:00PM: Abstract Number: 2098

Prioritizing Likely Causative Genes in Genome-Wide Association Studies (GWAS) Identified Risk Loci for Immune-Mediated Inflammatory Disorders Using Cell-Type Specific Expression Quantitative Loci (eQTL) Information

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2124

Racial Disparities in Lupus Pregnancy

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects

4:30PM-6:00PM: Abstract Number: 2109

Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)

Metabolic and Crystal Arthropathies I: Therapeutics

4:30PM-6:00PM: Abstract Number: 2133

Receptor Protein Tyrosine Phosphatase Alpha Enhances Rheumatoid Synovial Fibroblast Signaling and Promotes Arthritis in Mice

Rheumatoid Arthritis - Human Etiology and Pathogenesis II

4:30PM-6:00PM: Abstract Number: 2157

Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis

Vasculitis II

4:30PM-6:00PM: Abstract Number: 2139

Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy IV: Safety of Targeted Therapies

4:30PM-6:00PM: Abstract Number: 2125

Rheumatic and Non-Rheumatic Autoimmune Diseases in SLE Offspring

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects

4:30PM-6:00PM: Abstract Number: 2141

Risk of Cancer in Non-TNFi Biologics-Treated RA

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy IV: Safety of Targeted Therapies

4:30PM-6:00PM: Abstract Number: 2138

Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy IV: Safety of Targeted Therapies

4:30PM-6:00PM: Abstract Number: 2159

Second Temporal Artery Biopsies in Patients with Temporal Arteritis (TA)

Vasculitis II

4:30PM-6:00PM: Abstract Number: 2148

Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment:Treatment of PsA and SpA

4:30PM-6:00PM: Abstract Number: 2146

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment:Treatment of PsA and SpA

4:30PM-6:00PM: Abstract Number: 2170

Sleep Efficiency and Cardiovascular Risk Burden in Rheumatoid Arthritis

ARHP III: Epidemiology and Public Health

4:30PM-6:00PM: Abstract Number: 2103

Temporal Trends in Drug Prescription, Utilization and Costs Among Rheumatoid Arthritis (RA) Patients Show Wide Regional Variation Despite Universal Drug Coverage

Health Services Research II: Rheumatoid Arthritis Treatment and Healthcare Utilization

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].